Specialty pharmaceutical company Indivior (LSE: INDV) is rising today after the company issued an upbeat trading statement for the first half of the year.
The company announced that trading for the period was ahead of expectations and management raised its guidance for the full year.
Indivior now expects full-year 2015 revenue of between $935m to $965m, compared to its previous guidance of $850m to $880m. Net income is now expected to be in the region of $185m to $210m, compared to previous guidance of $130m to $155m.
Should you invest £1,000 in AstraZeneca right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?
First-half pre-tax profit fell to $199m, down from $327m as reported last year.
Lack of diversification
Even though Indivior’s results beat expectations, the company is still a one-trick pony. Indeed, with only one key treatment on the market at present, Indivior’s success is highly dependent upon the company’s ability to monetise its drug pipeline.
Indivior’s key product is its opioid dependence treatment Suboxone Sublingual Film, the sales of which are falling as low-cost generic competitors break Indivior’s grip over the market.
To a certain extent, AstraZeneca (LSE: AZN) is in the same position as Indivior. As Astra’s sales from legacy drugs are falling, the company is pinning its hopes on a raft on new treatments to help return the company to growth.
However, as all investors know, diversification is key to achieving the best returns while minimising risk. And when it comes to treatment diversification, Astra’s broad offering should win over investors every time.
It’s estimated that only 7% of new drugs make it from the initial discovery stage to commercial sale, which means that it’s crucial for pharmaceutical companies to hedge their bets by developing a broad range of new potential treatments.
Astra has 222 new products currently under development. On the other hand, Indivior is expecting one new product roll-out every year from 2016 to 2020 — assuming everything goes to plan. In other words, Indivior only has four new products under development.
Premium valuation
Indivior’s performance has eclipsed that of Astra over the past six months. While Astra’s shares have slipped by 11.4% since the end of January, Indivior’s shares have gained a staggering 53% over the same period.
However, these gains have left Indivior looking expensive, considering the company’s earnings are set to slide by more than 40% this year and a further 20% during 2016. At present levels, Indivior is trading at a forward P/E of 14.1 and a 2016 P/E of 17.5. City analysts believe the company’s shares will support a dividend yield of 2.5% this year.
In comparison, Astra’s earnings per share are set to fall by around 1% this year and 3% during 2016 before returning to growth during 2017. What’s more, the group currently trades at a forward P/E of 15.6 and supports a dividend yield of 4.3%.
The bottom line
Overall, Astra is cheaper, supports a more attractive dividend yield, and has a greater number of new treatments under development than Indivior.
